Variation of faecal calprotectin level within the first three months after bowel resection is predictive of endoscopic postoperative recurrence in Crohn's disease

Dig Liver Dis. 2020 Jul;52(7):740-744. doi: 10.1016/j.dld.2020.03.020. Epub 2020 May 20.

Abstract

Background: Early prediction of postoperative recurrence (POR) remains a major concern in Crohn's disease (CD).

Aims: To assess serial faecal calprotectin (Fcal) monitoring within the first three months to predict CD endoscopic POR.

Methods: In a multicenter randomized controlled trial, CD patients received azathioprine 2.5 mg/kg/day with oral curcumin (3 g/day) or placebo. Fcal was measured at baseline, one month (M1) and M3. Endoscopic POR at M6 was defined as Rutgeerts' index ≥ i2b (central reading).

Results: Among the 48 patients included, there was no significant difference of median Fcal levels at baseline (p = 0.15), M1 (p = 0.44) and M3 (p = 0.28) between patients with or without endoscopic POR at M6. Fcal kinetics during the first 3 months after surgery was significantly different between the patients with or without POR at M6 (p = 0.021). The median variation between Fcal level at baseline and M3 (ΔFcal M3-M0) was significantly higher in patients with endoscopic POR compared to those without POR (p = 0.01). ΔFcal M3-M0 >+10% demonstrated the best performances to predict endoscopic POR at M6 (AUC=0.73, sensitivity=64.7%[41.1-82.7], specificity=87.5%[68.0-96.3], negative predictive value=77.8%[57.5-91.4] and positive predictive value=78.6%[49.2-95.3]).

Conclusion: Fcal variation within the first three months after ileocolonic resection is a promising predictor of early endoscopic POR in CD patients.

Keywords: Crohn's disease; Faecal calprotectin; Monitoring; Postoperative recurrence; Surgery.

Publication types

  • Clinical Trial, Phase III
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Azathioprine / therapeutic use
  • Biomarkers / metabolism
  • Colectomy*
  • Crohn Disease / drug therapy
  • Crohn Disease / metabolism
  • Crohn Disease / surgery*
  • Curcumin / therapeutic use
  • Feces / chemistry*
  • Female
  • France
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Leukocyte L1 Antigen Complex / metabolism*
  • Male
  • Middle Aged
  • Postoperative Period
  • Predictive Value of Tests
  • ROC Curve
  • Recurrence
  • Remission Induction
  • Severity of Illness Index
  • Time Factors
  • Treatment Outcome
  • Young Adult

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Biomarkers
  • Immunosuppressive Agents
  • Leukocyte L1 Antigen Complex
  • Curcumin
  • Azathioprine